Tue.Sep 10, 2024

article thumbnail

After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned

Fierce Pharma

After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.

296
296
article thumbnail

In conversation with the library community: The Pulse of the Library report

Clarivate

New Clarivate report assesses current and expected trends and investigates the impact of technologies, including AI, on librarians and their communities through a global survey of academic, national and public libraries. Advanced technologies, in particular Artificial Intelligence (AI), are reshaping the world of education and research, offering new possibilities for enhancing learning outcomes, accelerating discovery and improving content accessibility.

Education 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After FDA rejection, Sanofi and Regeneron show data that could pave way for Dupixent to treat hives condition

Fierce Pharma

Eleven months after sustaining a rejection from the FDA for Dupixent to treat c | Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria, Sanofi and Regeneron have presented data from a phase 3 trial that could help push the megablockbuster across the finish line in the indication.

FDA 144
article thumbnail

GSK’s Depemokimab Significantly Reduces Asthma Exacerbations

Pharmaceutical Commerce

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

Patients 105
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

A closer look at the Fierce 50

Fierce Pharma

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special | In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report.

article thumbnail

Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier

MedCity News

Some of the most difficult processes for digital health startups to navigate are those related to reimbursement and coding. Startups will often need to create entirely new codes for their products, so they should start thinking about this sooner rather than later, experts said at a recent conference. The post Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier appeared first on MedCity News.

111
111

More Trending

article thumbnail

Parenting: The New Mental Health Threat?

MedCity News

A CEO and father of two reflects on the Surgeon General’s recent advisory, evolving pressures on today’s parents and the impact on mental health. The post Parenting: The New Mental Health Threat? appeared first on MedCity News.

article thumbnail

Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic

Pharmaceutical Technology

Baltimore opted out of a national settlement last year, instead pursuing its own claim against the opioid manufacturer.

article thumbnail

Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

MedCity News

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso. The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug appeared first on MedCity News.

article thumbnail

WCLC: Bayer, Boehringer face off on HER2 cancers

pharmaphorum

Bayer and Boehringer present data on competing oral HER2 drugs at WCLC, as they run phase 3 trials in NSCLC with HER2 activations.

72
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Medicare Advantage Audit Ready with AI

MedCity News

Adding generative AI and other AI tools to coding and chart review practices streamlines a complex process and better positions plans for risk adjustment audits. The post Medicare Advantage Audit Ready with AI appeared first on MedCity News.

91
article thumbnail

Comparing DWPI abstracts to generative AI summaries: You asked, and we answered

Clarivate

Reliable insights require quality monitoring and a high level of accuracy. New generative artificial intelligence (AI) and large language model (LLM) technologies offer new possibilities for patent researchers. They can create workflow efficiencies for those who want to capture quick insights from the ever-expanding volume of global patent publications.

article thumbnail

GSK ultra-long-acting biologic shows Phase III potential

European Pharmaceutical Review

Results from GSK’s two Phase III clinical trials evaluating the biologic depemokimab has shown promise in extending dosing intervals in severe asthma, with individuals just requiring two doses annually. The injectable treatment was assessed against placebo in the SWIFT-1 and SWIFT-2 trials and open label extension study (AGILE). It is the first ultra-long-acting biologic to be evaluated in Phase III trials.

article thumbnail

Pharma Pulse 9/10/24: Counterfeit Weight Loss Drugs & Potential Health Risks, AI Isn't Magic & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Phase 2 PREDICT-ILD imaging study commences in interstitial lung disease

PharmaTimes

Molecular imaging agent 99mTc-maraciclatide to aid in disease prognostication

88
article thumbnail

AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients

Pharmaceutical Technology

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall survival than chemotherapy.

article thumbnail

APL and CurifyLabs partner to support patients with 3D printing medicine technology

PharmaTimes

Critically ill individuals will benefit from futuristic tech

article thumbnail

Melissa Krebs Shares GelSana’s Vision for Innovative Wound Care Solutions

PharmExec

In this interview, Melissa Krebs, CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Editorial Advisory Board Spotlight: Susan J. Schniepp

PharmaTech

Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology EuropeT, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future.

article thumbnail

Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

PharmExec

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.

article thumbnail

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

PharmaTech

The 2024 CPHI Pharma Awards comprise finalists spanning 14 categories and includes awards for future leaders, women of the year, and an “at the heart of pharma” category.

Pharma 52
article thumbnail

Commenting on Eli Lilly's Recent Announcement of Offering Zepbound DTC

PharmExec

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Terns files $125m financing after positive obesity data

pharmaphorum

Terns Pharma files $125m+ public offering to support trials of its oral GLP-1 agonist candidate TERN-601 for obesity.

Pharma 64
article thumbnail

A new way of determining a drug’s value — with health equity in mind

PharmaVoice

Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.

52
article thumbnail

ERS: GSK reveals data behind new asthma hope depemokimab

pharmaphorum

GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.

59
article thumbnail

The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of Medicine

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

ERS: Analysis of speech spots COPD flare-ups

pharmaphorum

Researchers have shown that COPD exacerbations can be predicted by looking for vocal biomarkers in recorded speech

59
article thumbnail

From Endemic to POC: The Journey Pharma Marketers Need to Tread

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

EASD 2024: New developments in presymptomatic type 1 diabetes screening

Pharmaceutical Technology

The study involved over 3,600 participants, including FDRs of newly diagnosed type 1 diabetes patients in Denmark and children in Sweden.

article thumbnail

Evernorth to Provide Stelara Biosimilar for 0$ Out-of-Pocket

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A